Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
PhoenixBio Co., Ltd. specializes in the development of biopharmaceuticals, particularly in the area of regenerative medicine and cell therapy. The company has a strong foothold in Japan and is expanding its presence in the Asia-Pacific region, leveraging its proprietary technology in stem cell research to differentiate itself from competitors.
PhoenixBio generates revenue primarily through the sale of its biopharmaceutical products, which are developed using proprietary stem cell technology. The company has established partnerships with various research institutions and pharmaceutical companies, allowing it to monetize its research capabilities while maintaining a strong pipeline of innovative therapies.
Regulatory approvals for new therapies, particularly in Japan and Asia-Pacific markets
Partnership announcements with larger pharmaceutical companies
Clinical trial results impacting product pipeline
Market expansion into new geographies
Regulatory changes affecting approval processes for biopharmaceuticals
Technological advancements by competitors that could render current therapies obsolete
Emergence of new entrants in the stem cell therapy market
Aggressive pricing strategies from larger pharmaceutical companies
Potential liquidity risks if cash flow does not improve significantly
Dependence on external funding for R&D initiatives
moderate - The biotechnology sector is somewhat insulated from economic cycles, but funding for research and development can be affected by broader economic conditions.
Higher interest rates can increase the cost of capital for PhoenixBio, impacting its ability to fund R&D and clinical trials, which may pressure valuations.
minimal - The company has a low debt-to-equity ratio of 0.31, indicating limited reliance on external financing.
growth - Investors are likely drawn to the potential for high returns from innovative therapies and expanding market presence.
high - The stock has shown significant price fluctuations, evidenced by a 29.5% decline over the past three months.
